79 related articles for article (PubMed ID: 16796777)
21. Abnormal cytogenetics predict poor survival after high-dose therapy and autologous blood cell transplantation in multiple myeloma.
Rajkumar S; Fonseca R; Lacy M; Witzig T; Lust J; Greipp P; Therneau T; Kyle R; Litzow M; Gertz M
Bone Marrow Transplant; 1999 Sep; 24(5):497-503. PubMed ID: 10482933
[TBL] [Abstract][Full Text] [Related]
22. Impact of complete remission with intensive therapy in patients with responsive multiple myeloma.
Alexanian R; Weber D; Giralt S; Dimopoulos M; Delasalle K; Smith T; Champlin R
Bone Marrow Transplant; 2001 May; 27(10):1037-43. PubMed ID: 11438818
[TBL] [Abstract][Full Text] [Related]
23. Controversy in multiple myeloma transplants: tandem autotransplants and mini-allografts.
Vesole DH; Simic A; Lazarus HM
Bone Marrow Transplant; 2001 Oct; 28(8):725-35. PubMed ID: 11781623
[TBL] [Abstract][Full Text] [Related]
24. Long-term outcome results of the first tandem autotransplant trial for multiple myeloma.
Barlogie B; Tricot GJ; van Rhee F; Angtuaco E; Walker R; Epstein J; Shaughnessy JD; Jagannath S; Bolejack V; Gurley J; Hoering A; Vesole D; Desikan R; Siegel D; Mehta J; Singhal S; Munshi NC; Dhodapkar M; Jenkins B; Attal M; Harousseau JL; Crowley J
Br J Haematol; 2006 Oct; 135(2):158-64. PubMed ID: 16939489
[TBL] [Abstract][Full Text] [Related]
25. Impact of high-risk cytogenetics and achievement of molecular remission on long-term freedom from disease after autologous-allogeneic tandem transplantation in patients with multiple myeloma.
Kröger N; Badbaran A; Zabelina T; Ayuk F; Wolschke C; Alchalby H; Klyuchnikov E; Atanackovic D; Schilling G; Hansen T; Schwarz S; Heinzelmann M; Zeschke S; Bacher U; Stübig T; Fehse B; Zander AR
Biol Blood Marrow Transplant; 2013 Mar; 19(3):398-404. PubMed ID: 23078786
[TBL] [Abstract][Full Text] [Related]
26. Retrospective analysis of the results of high-dose chemotherapy with the support of autologous blood stem cells in patients with multiple myeloma. The experience of a single centre.
Kořen J; Spička I; Straub J; Vacková B; Trnková M; Pohlreich D; Pytlík R; Trněný M
Prague Med Rep; 2010; 111(3):207-18. PubMed ID: 20946721
[TBL] [Abstract][Full Text] [Related]
27. An incremental response to high-dose therapy in multiple myeloma.
Hawkins T; Horvath N; Rawling C; Bayly J; Andary C; Dyson P; Ho J; Dart G; Juttner C; To B
Bone Marrow Transplant; 1996 Jun; 17(6):929-35. PubMed ID: 8807096
[TBL] [Abstract][Full Text] [Related]
28. Thiotepa, busulfan, cyclophosphamide (TBC) and autologous hematopoietic transplantation: an intensive regimen for the treatment of multiple myeloma.
Shimoni A; Smith TL; Aleman A; Weber D; Dimopoulos M; Anderlini P; Andersson B; Claxton D; Ueno NT; Khouri I; Donato M; Korbling M; Alexanian R; Champlin R; Giralt S
Bone Marrow Transplant; 2001 Apr; 27(8):821-8. PubMed ID: 11477439
[TBL] [Abstract][Full Text] [Related]
29. Periodic morphologic, cytogenetic and clonality evaluation after autologous peripheral blood progenitor cell transplantation in patients with lymphoproliferative malignancies.
Laurenti L; Chiusolo P; Garzia MG; Zini G; Sorà F; Piccirillo N; Piccioni P; Zollino M; Leone G; Sica S
Haematologica; 2002 Jan; 87(1):59-66. PubMed ID: 11801466
[TBL] [Abstract][Full Text] [Related]
30. Attainment of at least a very good partial response after induction treatment is an important surrogate of longer survival for multiple myeloma.
Tan D; Lao Z; Loh Y; Ng HJ; Chuah C; Wong GC; Koh M; Linn YC; Lim LC; Tien SL; Lee LH; Goh YT; Hwang W
Bone Marrow Transplant; 2010 Nov; 45(11):1625-30. PubMed ID: 20154737
[TBL] [Abstract][Full Text] [Related]
31. Outcome assessment of a population-based group of 195 unselected myeloma patients under 70 years of age offered intensive treatment.
Powles R; Raje N; Milan S; Millar B; Shepherd V; Mehta J; Singhal S; Kulkarni S; Viner C; Gore M; Cunningham D; Treleaven J
Bone Marrow Transplant; 1997 Sep; 20(6):435-43. PubMed ID: 9313875
[TBL] [Abstract][Full Text] [Related]
32. Single versus double autologous stem-cell transplantation for multiple myeloma.
Attal M; Harousseau JL; Facon T; Guilhot F; Doyen C; Fuzibet JG; Monconduit M; Hulin C; Caillot D; Bouabdallah R; Voillat L; Sotto JJ; Grosbois B; Bataille R;
N Engl J Med; 2003 Dec; 349(26):2495-502. PubMed ID: 14695409
[TBL] [Abstract][Full Text] [Related]
33. Retrospective comparison of bortezomib-containing regimens with vincristine-doxorubicin-dexamethasone (VAD) as induction treatment prior to autologous stem cell transplantation for multiple myeloma.
Eom HS; Min CK; Cho BS; Lee S; Lee JW; Min WS; Kim CC; Kim M; Kim Y
Jpn J Clin Oncol; 2009 Jul; 39(7):449-55. PubMed ID: 19487425
[TBL] [Abstract][Full Text] [Related]
34. Long-term outcome after allogeneic stem-cell transplantation with reduced-intensity conditioning in patients with multiple myeloma.
El-Cheikh J; Crocchiolo R; Furst S; Stoppa AM; Ladaique P; Faucher C; Calmels B; Lemarie C; De Colella JM; Granata A; Coso D; Bouabdallah R; Chabannon C; Blaise D
Am J Hematol; 2013 May; 88(5):370-4. PubMed ID: 23460414
[TBL] [Abstract][Full Text] [Related]
35. Feasibility and outcome of tandem stem cell autotransplants in multiple myeloma.
Galli M; Nicolucci A; Valentini M; Belfiglio M; Delaini F; Crippa C; Barbui AM; Giussani U; Rambaldi A; Barbui T
Haematologica; 2005 Dec; 90(12):1643-9. PubMed ID: 16330437
[TBL] [Abstract][Full Text] [Related]
36. [Tandem transplantation with peripheral autologous hematopoietic blood stem cells in treatment of oncologic and hematologic malignancies. Initial results of the Donauspital, Vienna].
Ruckser R; Kier P; Sebesta C; Kittl E; Kurz M; Selleny S; Höniger S; Scherz M; Habertheuer KH; Zelenka P
Wien Med Wochenschr; 1995; 145(2-3):41-4, 46-7. PubMed ID: 7762251
[TBL] [Abstract][Full Text] [Related]
37. Combinations of cytogenetics and international scoring system can predict poor prognosis in multiple myeloma after high-dose chemotherapy and autologous stem cell transplantation.
Inamoto Y; Kurahashi S; Imahashi N; Fukushima N; Adachi T; Kinoshita T; Tsushita K; Miyamura K; Naoe T; Sugiura I
Am J Hematol; 2009 May; 84(5):283-6. PubMed ID: 19338045
[TBL] [Abstract][Full Text] [Related]
38. Efficacy of up-front treatment with a double stem cell transplantation in multiple myeloma.
Eom KS; Min CK; Lee S; Kim YJ; Kim SY; Kim HJ; Lee JW; Min WS; Kim CC
Jpn J Clin Oncol; 2006 Jul; 36(7):432-8. PubMed ID: 16782727
[TBL] [Abstract][Full Text] [Related]
39. Induction therapy with vincristine, adriamycin, dexamethasone (VAD) and intermediate-dose melphalan (IDM) followed by autologous or allogeneic stem cell transplantation in newly diagnosed multiple myeloma.
Lokhorst HM; Sonneveld P; Cornelissen JJ; Joosten P; van Marwijk Kooy M; Meinema J; Nieuwenhuis HK; van Oers MH; Richel DJ; Segeren CN; Veth G; Verdonck LF; Wijermans PW
Bone Marrow Transplant; 1999 Feb; 23(4):317-22. PubMed ID: 10100574
[TBL] [Abstract][Full Text] [Related]
40. Secondary monoclonal gammopathy of undetermined significance is frequently associated with high response rate and superior survival in patients with plasma cell dyscrasias.
Zou D; An G; Zhu G; Wang J; Shi L; Meng H; Xu Y; Sui W; Deng S; Zhan F; Qiu L
Biol Blood Marrow Transplant; 2014 Mar; 20(3):319-25. PubMed ID: 24296491
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
